I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $293.7M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
Advanced |
New York |
11/29/05 |
$8 |
Canaan Partners and Wheatley Partners co-led the Series B financing, which also included existing investors; Walter Greenblatt & Associates LLC was financial adviser |
Alimera |
Atlanta |
11/30/05 |
$31.8 |
The Series B financing round was led by Venrock Associates and included original investors BA Venture Partners, Domain Associates, Intersouth Partners and Polaris Venture Partners |
Antisense |
Regensburg, Germany |
11/30/05 |
$18 |
The investment was provided by German MIG funds |
CeNeRx |
Research Triangle Park, N.C. |
11/29/05 |
$18.5 |
The Series A financing round was led by Perseus- Soros BioPharmaceutical Fund, with participation from L Capital Partners, A.M. Pappas & Associates and Wistar Morris |
CytImmune |
Rockville, Md. |
11/15/05 |
$5 |
The financing was a combination of a private investment and state funding from Maryland' s Department of Business and Economic Development |
Edison |
San Jose, Calif. |
11/29/05 |
$2.8 |
The Series A round was led by Paul Avery |
4SC AG |
Martinsried, Germany |
11/30/05 |
€10.16 (US$11.9) |
The pre-listing financing entailed the sale of about 2.4M shares at €4.24 per share; Conrad Hinrich Donner Bank AG coordinated the deal |
Fovea |
Paris |
11/7/05 |
€20.5 (US$24.5) |
The Series A financing round was led by Sofinnova Partners and included Abingworth Management, The Wellcome Trust, GIMV and Credit Agricole Private Equity |
Gene-IT Inc. |
Worcester, Mass. |
11/30/05 |
$4.1 |
The Series A financing was led by Cross Atlantic Partners and Milestone Venture Partners, and included Société Générale Asset Management Alternative Investments |
Guava |
Hayward, Calif. |
11/29/05 |
$7 |
The financing was provided by existing investors Abingworth Life Science Investment, Granite Global Ventures, HLM Venture Partners, MDS Capital Corp., ProQuest Investments and Skyline Ventures |
Inotek |
Beverly, Mass. |
11/17/05 |
$10 |
Inotek raised $10M in the second tranche of a $35M Series B financing; $25M was raised In August; new investors included Caisse de depot et placement du Quebec and Pitango Venture Capital |
IntegraGen |
Evry, France |
11/17/05 |
€8 (US$9.4) |
Investors in the Series B financing round included CDC Enterprises Innovation, AGF Private Equity, Bioam, SGAM Alternative Investments and Baytech Venture Capital |
iQur Ltd. |
Southampton, UK |
11/8/05 |
£2.6 (US$4.5) |
Details on the £2.6 follow-on financing were not disclosed; the company formerly was named HepCgen Ltd. |
Lentigen Corp. |
Baltimore |
11/30/05 |
ND |
The company secured undisclosed seed and Series A financing from Greenwich Biotech Ventures |
Mersana |
Cambridge, Mass. |
11/8/05 |
$21 |
Fidelity Biosciences and ProQuest Investments led the financing round; also participating were Rho Ventures and previous investors PureTech Ventures, Cape Family Fund LLC, Harris & Harris Group Inc. and Lansing Brown Investments LLC |
NuPathe Inc. |
Conshohocken, Pa. |
11/8/05 |
$0.5 |
BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, led the seed funding round |
OncoMethylome |
Leige, Belgium |
11/2/05 |
€15 (US$17.7) |
The Series B financing round was led by Edmond de Rothschild Investment Partners; existing investors ING Belgium, Life Sciences Partners, PolyTechnos Venture-Partners, Meusinvest and Technowal also participated |
Portola |
South San Francisco |
11/8/05 |
$46 |
The Series B financing round was led by Advanced Technology Ventures; also participating were Alta Partners and previous investors Abingworth Management, Frazier Healthcare Ventures, MPM Capital, Prospect Ventures and Sutter Hill Ventures |
PTC |
South Plainfield, N.J. |
11/10/05 |
$26.6 |
The financing was led by existing investors Credit Suisse First Boston Private Equity and HBM BioVentures, with participation from Vulcan Ventures, Novo A/S, Delphi Ventures, Bay City Capital, Novartis BioVentures, Amgen Ventures and HealthCap |
Rincon |
San Diego |
11/15/05 |
$4.7 |
The financing was led by Paperboy Ventures |
Spear |
London |
11/28/05 |
$8.5 |
Advent International invested in the financing round |
Syntaxin Ltd. |
Salisbury, UK |
11/15/05 |
£3 (US$5.2) | Abingworth Management Ltd. invested in the company, which was spun out from the UK Health Protection Agency |
Vital |
San Diego |
11/1/05 |
$8 | MedVenture Associates led the first closing of a Series B financing; also participating were Valley Ventures, Paragon Venture Partners, Toucan Capital and individual investors |
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $1M | ||||
Company |
Partner |
Amt. |
Triggering |
Details (Date) |
Discovery |
Seikagaku Corp. (Japan) |
ND |
Milestone payment |
Triggered by Seikagaku's advancement of a compound identified by DPI in their collaboration to the next stage of development (11/9) |
Metabolex |
Astellas Pharma Inc. (Japan) |
ND |
Milestone payment |
Triggered by Astellas' selection of additional validated targets for drug screening and development in their collaboration (11/8) |
Medarex Inc. |
Bristol-Myers Squibb Co. |
ND |
Milestone payment |
Triggered by advancement into clinical trials of BMS-66513, a fully human antibody that targets CD137 developed using Medarex technology (11/15) |
Micromet |
MedImmune Inc. (MEDI) |
ND |
Milestone payment |
Triggered by Micromet's generation of BiTE molecules against a MedImmune oncology target (11/21) |
Neose |
Novo Nordisk A/S (Denmark) |
ND |
Milestone payment |
The payment stems from November 2003 deal to use Neose's GlycoPEGylation technol- ogy to develop next-generation versions of already-marketed therapeutic proteins (11/21) |
Vical Inc. |
Merck & Co. Inc. |
$1 |
Milestone payment |
Triggered by Merck's initiation of a Phase I trial of a DNA cancer vaccine based on Vical's DNA gene delivery technology (11/8) |
VisiGen |
SeqWright Inc. |
ND |
Equity investment |
SeqWright is making an undisclosed follow-on investment in VisiGen (11/2) |
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Private company. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
To read more on related topics, click on one of the words below.